533 related articles for article (PubMed ID: 15234399)
1. Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation.
van der Heijden DJ; Westendorp IC; Riezebos RK; Kiemeneij F; Slagboom T; van der Wieken LR; Laarman GJ
J Am Coll Cardiol; 2004 Jul; 44(1):20-4. PubMed ID: 15234399
[TBL] [Abstract][Full Text] [Related]
2. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
[TBL] [Abstract][Full Text] [Related]
3. Diminishing returns...and too many choices...the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention.
Stadius ML
J Am Coll Cardiol; 2004 Jul; 44(1):25-7. PubMed ID: 15234400
[No Abstract] [Full Text] [Related]
4. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
Mangiacapra F; Barbato E; Patti G; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Wijns W; Di Sciascio G
JACC Cardiovasc Interv; 2010 Mar; 3(3):318-23. PubMed ID: 20298992
[TBL] [Abstract][Full Text] [Related]
5. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
[TBL] [Abstract][Full Text] [Related]
6. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.
Ang L; Thani KB; Ilapakurti M; Lee MS; Palakodeti V; Mahmud E
J Am Coll Cardiol; 2013 Jan; 61(1):23-34. PubMed ID: 23287370
[TBL] [Abstract][Full Text] [Related]
7. Treatment modalities of non-ST-elevation acute coronary syndromes in the real world. Results of the prospective R.OS.A.I.-2 registry.
Registro Osservazionale Angina Instabile Investigators
Ital Heart J; 2003 Nov; 4(11):782-90. PubMed ID: 14699708
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous kissing stents (SKS) technique for treating bifurcation lesions in medium-to-large size coronary arteries.
Sharma SK; Choudhury A; Lee J; Kim MC; Fisher E; Steinheimer AM; Kini AS
Am J Cardiol; 2004 Oct; 94(7):913-7. PubMed ID: 15464676
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
Calver AL; Blows LJ; Harmer S; Dawkins KD; Gray HH; Morgan JH; Simpson IA
Am Heart J; 2000 Sep; 140(3):483-91. PubMed ID: 10966552
[TBL] [Abstract][Full Text] [Related]
10. Does creatine kinase-MB (CK-MB) isoenzyme elevation following percutaneous coronary intervention with drug-eluting stents impact late clinical outcome?
Javaid A; Buch AN; Steinberg DH; Pinto Slottow T; Roy P; Pichard AD; Satler LF; Kent KM; Gevorkian N; Xue Z; Suddath WO; Waksman R
Catheter Cardiovasc Interv; 2007 Nov; 70(6):826-31. PubMed ID: 17621656
[TBL] [Abstract][Full Text] [Related]
11. Troponin I elevation and cardiac events after percutaneous coronary intervention.
Ricciardi MJ; Davidson CJ; Gubernikoff G; Beohar N; Eckman LJ; Parker MA; Bonow RO
Am Heart J; 2003 Mar; 145(3):522-8. PubMed ID: 12660677
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
[TBL] [Abstract][Full Text] [Related]
13. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
Chen WH; Lee PY; Ng W; Tse HF; Lau CP
J Am Coll Cardiol; 2004 Mar; 43(6):1122-6. PubMed ID: 15028378
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
15. Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial).
Bernardi V; Szarfer J; Summay G; Mendiz O; Sarmiento R; Alemparte MR; Gabay J; Berger PB
Am J Cardiol; 2007 Feb; 99(3):349-52. PubMed ID: 17261396
[TBL] [Abstract][Full Text] [Related]
16. Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention.
Nageh T; Sherwood RA; Harris BM; Byrne JA; Thomas MR
Int J Cardiol; 2003 Dec; 92(2-3):285-93. PubMed ID: 14659867
[TBL] [Abstract][Full Text] [Related]
17. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
18. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).
Bonz AW; Lengenfelder B; Strotmann J; Held S; Turschner O; Harre K; Wacker C; Waller C; Kochsiek N; Meesmann M; Neyses L; Schanzenbächer P; Ertl G; Voelker W
J Am Coll Cardiol; 2002 Aug; 40(4):662-8. PubMed ID: 12204495
[TBL] [Abstract][Full Text] [Related]
19. Troponin T, troponin I and creatine kinase-MB mass after elective coronary stenting.
La Vecchia L; Bedogni F; Finocchi G; Mezzena G; Martini M; Sartori M; Castellani A; Soffiati G; Vincenzi M
Coron Artery Dis; 1996 Jul; 7(7):535-40. PubMed ID: 8913672
[TBL] [Abstract][Full Text] [Related]
20. [Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
Patti G; Pasceri V; Nusca A; Di Sciascio G
Ital Heart J Suppl; 2005 Sep; 6(9):553-60. PubMed ID: 16281714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
